Olukotun of Arrowhead Pharma sells $676k in stock
- Investing.com
- English (USA)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- English (Nigeria)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Polski
- Português (Portugal)
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Arrowhead Pharmaceuticals Inc (ARWR)
Assess today's live Arrowhead Pharmaceuticals Inc (ARWR) share price, performance and insights using our live NASDAQ: ARWR stock exchange data.
Analyse the historical data and Arrowhead Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Arrowhead Pharma share price buy/sell indicators using real-time data (or discuss the Arrowhead Pharma (ARWR) stock price today with other investors in the Arrowhead Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ARWR share price (ISIN: US04280A1007) to enhance your trading decisions with our free investment tools and resources.
What Is the Arrowhead Pharmaceuticals Inc Share Price Today?
The Arrowhead Pharma share price today is 69.83.
What Is the Stock Symbol for Arrowhead Pharmaceuticals Inc
The stock symbol (or 'ticker') for Arrowhead Pharmaceuticals Inc is "ARWR."
What Stock Exchange Does Arrowhead Pharmaceuticals Inc Trade On?
Arrowhead Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Arrowhead Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Arrowhead Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Analyse the historical data and Arrowhead Pharmaceuticals Inc share price performance charts on this page. Our technical summary section provides analysis on Arrowhead Pharma share price buy/sell indicators using real-time data (or discuss the Arrowhead Pharma (ARWR) stock price today with other investors in the Arrowhead Pharma NASDAQ share price and sentiment chat forum).
Use the dropdown to select a relevant stock exchange for the current NASDAQ ARWR share price (ISIN: US04280A1007) to enhance your trading decisions with our free investment tools and resources.
What Is the Arrowhead Pharmaceuticals Inc Share Price Today?
The Arrowhead Pharma share price today is 69.83.
What Is the Stock Symbol for Arrowhead Pharmaceuticals Inc
The stock symbol (or 'ticker') for Arrowhead Pharmaceuticals Inc is "ARWR."
What Stock Exchange Does Arrowhead Pharmaceuticals Inc Trade On?
Arrowhead Pharmaceuticals Inc is listed and trades on the NASDAQ stock exchange.
Is Arrowhead Pharmaceuticals Inc a Good Stock to Buy?
Determining whether Arrowhead Pharmaceuticals Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, investors can sign up to InvestingPro, where they can assess share price, fair value and other essential metrics.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
68.48
70.49
52 wk Range
9.57
72.36
ARWR is not included in our AI-picked strategies. See which stocks are.
Fair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
68.4870.49
52 wk Range
9.5772.36
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
ARWR Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a stock's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Buy
Price Target
66.00
Downside
-5.48%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Olukotun of Arrowhead Pharma sells $676k in stock
- Investing.com
- Arrowhead Pharma CEO Anzalone sells $1.77m in stock
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy
Arrowhead Pharma Company Profile
Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. Its pipeline includes Plozasiran to reduce production of apolipoprotein C-III in Phase 3 studies; Zodasiran to reduce production of angiopoietin-like protein 3 in Phase 3 clinical trials; ARO-DIMER-PA, a dual functional RNAi molecule in a Phase 1/2a clinical trials; and ARO-PNPLA3, an investigational RNAi therapeutic in Phase 1 clinical trials. The company also develops ARO-INHBE, to reduce the hepatic expression of the INHBE gene and its secreted gene product, Activin E in Phase 1/2a clinical trials; ARO-ALK7 to silence adipocyte expression of the ACVR1C gene in Phase 1/2a clinical trials; ARO-RAGE to reduce production of the receptor for advanced glycation end products in Phase 1/2a clinical trials; and ARO-MAPT, an investigational RNAi-based therapy. In addition, it is developing ARO-C3 to reduce production of C3 in Phase 1/2a clinical trials; and ARO-CFB to reduce hepatic expression of CFB in a Phase 1/2a clinical trials. The company has collaboration and license Agreements with Glaxosmithkline Intellectual Property (No. 3) Limited; Takeda Pharmaceutical Company Limited; Amgen Inc.; and Sarepta Therapeutics, Inc. Arrowhead Pharmaceuticals, Inc. was founded in 2003 and is headquartered in Pasadena, California.
Arrowhead Pharmaceuticals Inc SWOT Analysis
Plozasiran's Promise | Arrowhead's lead drug candidate for FCS treatment nears potential FDA approval, showcasing strong Phase 3 results and advantages over competitors |
Strategic Pivot | Explore Arrowhead's shift towards cardio-metabolic treatments, allocating 75% of R&D spending to this promising area |
Market Valuation | Despite pipeline progress, stock underperforms biotech index. Analysts view current price as attractive, with targets ranging from $42 to $73 |
Future Horizons | Delve into Arrowhead's innovative integrin-targeting approach, potentially expanding applications in muscle-related disorders and differentiating from competitors |
Arrowhead Pharmaceuticals Inc Earnings Call Summary for Q4/2025
- Arrowhead reported Q4 2025 with $829M revenue from licensing deals, a net loss of $2M ($0.01/share), and stock rose 5.69% to $44.26 following FDA approval of Redemplo for FCS.
- The company has transitioned to commercial stage with Redemplo approval, maintaining $919M in cash/investments as of September 30, with runway extended into fiscal 2028.
- Arrowhead expects a $200M milestone payment from Sarepta in January 2026 and is preparing for data readouts on obesity treatments and pediatric studies for Redemplo.
- CEO Chris Anzalone emphasized the company's pipeline diversity and ambition to become a large, profitable biotech firm while maintaining rational drug pricing strategies.
- Management plans for potential Redemplo label expansion with an SNDA filing by 2026, while addressing challenges including pancreatitis risk and market adoption.
Last Updated: 25/11/2025, 22:56
Read Full TranscriptCompare ARWR to Peers and Sector
Metrics to compare | ARWR | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipARWRPeersSector | |
|---|---|---|---|---|
P/E Ratio | −5,814.6x | −2.3x | −0.6x | |
PEG Ratio | −58.29 | 0.09 | 0.00 | |
Price/Book | 20.3x | 3.3x | 2.6x | |
Price / LTM Sales | 11.4x | 10.1x | 3.2x | |
Upside (Analyst Target) | −1.9% | 23.1% | 41.8% | |
Fair Value Upside | Unlock | 2.1% | 5.1% | Unlock |
Analyst Ratings
9 Buy
4 Hold
0 Sell
Ratings:
13 analysts
Overall Consensus
Buy
Analysts 12-Month Price Target:
Average 66.00
(-5.48% Downside)
Earnings
Latest Release
Nov 25, 2025
EPS / Forecast
-0.11 / -0.3099
Revenue / Forecast
256.47M / 164.04M
People Also Watch
FAQ
What Is the Arrowhead Pharma (ARWR) Share Price Today?
The live Arrowhead Pharma share price today is 69.83
What Stock Exchange Does Arrowhead Pharma (ARWR) Trade On?
Arrowhead Pharma is listed and trades on the Nasdaq Stock Exchange.
What Is the Ticker (Stock Symbol) for Arrowhead Pharma?
The stock symbol (also called a 'ticker') for Arrowhead Pharma is "ARWR."
What Is the Current Arrowhead Pharma Market Cap?
As of today, Arrowhead Pharma market capitalisation is 9.48B.
What Is Arrowhead Pharma's (ARWR) Earnings Per Share (TTM)?
The Arrowhead Pharma EPS is currently -0.01 (Trailing Twelve Months).
When Is the Next Arrowhead Pharma Earnings Date?
Arrowhead Pharma's next earnings report will be released on 10 Feb 2026.
Is ARWR a Buy or Sell From a Technical Analyst Perspective?
Based on today's Arrowhead Pharma moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
How Many Times Has Arrowhead Pharma Stock Split?
Arrowhead Pharma has split 2 times. (See the ARWR stock split history page for full effective split date and price information.)
How Many Employees Does Arrowhead Pharma Have?
Arrowhead Pharma has 711 employees.
What is the current trading status of Arrowhead Pharma (ARWR)?
As of 24 Dec 2025, Arrowhead Pharma (ARWR) is trading at a price of 69.83, with a previous close of 69.00. The stock has fluctuated within a day range of 68.48 to 70.49, while its 52-week range spans from 9.57 to 72.36.
What Is Arrowhead Pharma (ARWR) Price Target According to Analysts?
The average 12-month price target for Arrowhead Pharma is USD66, with a high estimate of USD100 and a low estimate of USD17. 9 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an -5.48% Downside potential.
What Is the ARWR Premarket Price?
ARWR's last pre-market stock price is 69.43. The pre-market share volume is 3,020.00, and the stock has decreased by 0.43, or 0.62%.
What Is the ARWR After Hours Price?
ARWR's last after hours stock price is 70.43, the stock has decreased by 0.60, or 0.86%.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2025 - Fusion Media Limited. All Rights Reserved.